Xiaoxi Zhang

Jan 25, 2025 | nature.com | Scott Kopetz |Takayuki Yoshino |Eric Van Cutsem |Cathy Eng |Harpreet Wasan |Jayesh Desai | +9 more

Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC. The dual primary endpoint of progression-free survival is event driven; data were not mature at data cutoff. BREAKWATER met the other dual primary endpoint of objective response rate, demonstrating significant and clinically relevant improvement in objective response rate (EC+mFOLFOX6: 60.9%; SOC: 40.0%; odds ratio, 2.443; 95% confidence interval (CI): 1.403–4.253; 99.8% CI: 1.019–5.855; one-sided P = 0.0008). Median duration of response was 13.9 versus 11.1 months. At this first interim analysis of overall survival, the hazard ratio was 0.47 (95% CI: 0.318–0.691; repeated CI: 0.166–1.322). Serious adverse event rates were 37.7% versus 34.6%. The safety profiles were consistent with those known for each agent. BREAKWATER demonstrated a significantly improved response rate that was durable for first-line EC+mFOLFOX6 versus SOC in patients with BRAF V600E mCRC. ClinicalTrials.gov identifier: NCT04607421 . As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic colorectal cancer received the BRAF inhibitor encorafenib, the anti-EGFR monoclonal antibody cetuximab and chemotherapy mFOLFOX6 versus investigator’s choice of chemotherapy with or without bevacizumab, leading to an improved objective response rate, with the dual primary endpoint of progression free survival still maturing.

Jan 14, 2025 | mdpi.com | Jiahui Zhou |Tian Wu |Xiaoxi Zhang |Jiang Yu

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jul 19, 2023 | mdpi.com | Xiaoxi Zhang |Xiaojun Zhang |Jianbo Yuan |Fuhua Li

AltmetricshareShareannouncementHelpformat_quoteCitethumb_up... Endorsetextsms... CommentNeed Help? SupportFind support for a specific problem in the support section of our website. Get SupportFeedback Please let us know what you think of our products and services. Give FeedbackInformationVisit our dedicated information section to learn more about MDPI.

Apr 22, 2023 | arxiv.org | Zhi Zhou |Xiaoxi Zhang |Xu Chen

arXiv:2304.11374 (cs) Download a PDF of the paper titled Towards Carbon-Neutral Edge Computing: Greening Edge AI by Harnessing Spot and Future Carbon Markets, by Huirong Ma and Zhi Zhou and Xiaoxi Zhang and Xu Chen Download PDF Submission history From: Xu Chen [ view email] [v1] Sat, 22 Apr 2023 11:14:16 UTC (664 KB) Bibliographic Tools Bibliographic Explorer Toggle Bibliographic Explorer () Litmaps Toggle Litmaps (What is Litmaps?) scite.ai Toggle scite Smart Citations (What are Smart...